AZTRAzitra, Inc. stock chart & analysis

Conviction 36HealthcareScan · Mon, Oct 26, 2026

Azitra, Inc. (AZTR) closed at $1.51 (+40.79%) on Oct 26, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 36, RS Rating 5, -90.8% from its 52-week high, -62.0% year to date. Sector: Healthcare · Pharmaceutical Preparations.

AZTR$1.51+40.79%

ResistanceSupportVol 14

Vol MA14 5.9M

Jul 17Aug 4Aug 21Sep 9Sep 28Oct 26

Why AZTR moved

From the StockSetups movers recaps that covered AZTR, newest first. A recap states what was known that day.

Oct 26, 2026Close+40.8%
Azitra closed up 40.8% at $1.51 on 81.8 million shares, about 20 times its 20-day average of 4.1 million. Market cap is about $4.3 million. An intraday report had the stock up roughly 101% at one point, so much of the gain faded into the close.
Top Stock Movers Oct 26, 2026: Why GCTK, CLRO, SGRY Surged →

Azitra, Inc.Pharmaceutical Preparationswww.azitrainc.com ↗

Price1.51

Change+40.79%

Gap-0.23%

Rel volume1432.75×

Avg volume4.14M

Avg $ vol6.28M

SMA 202.13

SMA 502.26

SMA 2002.93

Price vs 50-33.30%

Price vs 200-48.44%

MA stackbearish

50/200 cross—

Supertrenddown · 2.10

RSI (14)36

MACD hist-0.09

MACD cross—

Stoch %K / %D40 / 20

ADX (14)38

+DI / −DI11 / 35

RSI divergence—

MACD divergence—

ATR %20.76%

ADR %16.56%

52w high16.35

52w low0.7770

From 52w high-90.76%

Above 52w low+94.34%

New 52w highNo

SqueezeOff

Bollinger width76.57%

%B0.12

Donchian pos37.76%

Donchian high2.72

Donchian low0.7770

AVWAP (52w high)3.15

vs AVWAP high-52.01%

AVWAP (52w low)1.51

vs AVWAP low+0.04%

OBV trendUp

Chaikin MF (20)-0.00

Today vs 20d1432.75×

Avg vol (14d)5.9M

Avg vol (20d)4.14M

Avg $ vol (20d)6.28M

Market cap91.51M

RS Rating5 / 99

RS 3m (vs SPY)-26.13%

RS 6m (vs SPY)-63.53%

RS line new highNo

Trend template1/8

Technical rank8.1

1 week-23.74%

1 month-41.13%

3 months-24.20%

6 months-54.20%

1 year-85.49%

YTD-61.98%

P/E-8.35

P/B12.48

P/S—

P/FCF-8.14

EPS-2.25

Div yield—

ROE-149.37%

ROA-122.87%

Debt/Eq—

Current4.86

EV/EBITDA-7.83

Gross margin—

Net margin—

Rev growth-100.00%

EPS growth-22.17%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value84.78M

Revenue—

Net income-3.35M

Gross profit—

Free cash flow-11.25M

IndustryPharmaceutical Preparations

ExchangeNYSE

Shares out16.19M

Employees13

ListedFri, Jun 16, 2023

Free float15.32M

Float %96.4%

Short interest1.37M

Days to cover0.3d

Short volume55.7%

Squeeze score45 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction36 / 100

Pattern quality—

Tech rank8.1 / 100

Group rank—

Status laneNo active setup

Setup direction—

Pattern family

Resistance2.85

Support2.11

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

AZTR technical analysis

Trend

AZTR is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 33.3% below the 50-day ($2.26) and 48.4% below the 200-day ($2.93). ADX(14) at 38 points to a strong, established trend. It meets 1 of 8 trend-template criteria.

Momentum

RSI(14) is 36, in the bearish half of its range. The MACD histogram is negative. Its RS Rating of 5 puts its weighted 12-month performance ahead of about 5% of the US market.

Volume and volatility

Volume on the latest session ran 1432.8× its 20-day average. It trades about $6.3M a day on average. ATR(14) is $0.3135, 20.8% of price — its typical daily range. On-balance volume is trending up.

Key levels

The chart pattern's support is $2.11 and its resistance $2.85. The 52-week range is $0.7770 to $16.35; price is 90.8% below the high and 94.3% above the low. The VWAP anchored at the 52-week high is $3.15, above price.

Performance

AZTR returned -23.7% (1 week), -41.1% (1 month), -24.2% (3 months), -54.2% (6 months), -85.5% (1 year), -62.0% (year to date).

About Azitra, Inc.

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Pharmaceutical Preparations · Listed 2023 · 13 employees

Insider activity

SEC Form 4 transactions in AZTR

Insider	Side	Shares	Value	Traded	Filed
Salva Francisco D. President and CEO · Common Stock · 2026-06-16	Convert	4.06M	—	2026-06-16	2026-06-18
Salva Francisco D. President and CEO · Series A Convertible Non-Redeemable Preferred Stock · 2026-06-16	Convert	500	—	2026-06-16	2026-06-18
Whitfill Travis Chief Operating Officer · Stock Options (Right To Buy) · 2026-04-20	Grant	64.3K	$0	2026-04-20	2026-04-22
Salva Francisco D. President and CEO · Stock Options (Right To Buy) · 2026-04-20	Grant	220.88K	$0	2026-04-20	2026-04-22
Staskey Norm Chief Financial Officer · Stock Options (Right To Buy) · 2026-04-20	Grant	35.52K	$0	2026-04-20	2026-04-22

SEC filings

EDGAR filings in AZTR · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.